NeuroproteXeon have completed a distribution agreement with Linde AG for XENEXTM (xenon by inhalation) for Post Cardiac Arrest Syndrome (PCAS) for the European Union plus United Kingdom, Switzerland, Norway and Iceland.
The agreement includes a multi-tiered royalty and €23m ($27m) in milestone payments. The two key milestone payments are on approval for PCAS from the European Medicines Agency (EMA) and when Linde reaches cumulative sales of €100m ($119m) – provided this occurs in the first four years following approval.
Bill Burns, CEO of NeuroproteXeon, was elated with the agreement. He said, “When we started the company we believed the nitric oxide business model established by Linde, and employed by Mallinckrodt in North America, was going to be our go to market strategy. To be able to partner with both these companies establishes a terrific platform for mutual success.”
... to continue reading you must be subscribed
